|Bid||60.05 x 200|
|Ask||62.10 x 100|
|Day's Range||66.20 - 69.05|
|52 Week Range||28.35 - 136.90|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 1, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||98.56|
Puma Biotechnology, Inc. , a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, March 1, 2018 following release of its fourth quarter and full year 2017 financial results.
NEW YORK, NY / ACCESSWIRE / February 15, 2018 / U.S. markets rallied sharply from early losses Wednesday as inflation fears appear to be easing on Wall Street. The Dow Jones Industrial Average jumped 1.03 ...
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 3:30 p.m.
Puma (PBYI) enters an exclusive agreement with CANbridge under which the latter will seek regulatory approval for Nerlynx in China and develop and commercialize it in the region.
Puma Biotechnology, Inc. , a biopharmaceutical company, and CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, have entered into an exclusive agreement under which CANbridge will develop and commercialize NERLYNX® in mainland China, Taiwan, Hong Kong, and Macau .
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that initial results from the company’s ongoing SUMMIT Phase II ‘basket’ clinical trial of PB272 in patients with tumors harboring HER2 or HER3 mutations were published in the journal Nature.
Puma's licensing agreement for breast cancer drug Nerlynx won't inhibit takeover interest for Puma, an analyst said Tuesday.
Investors need to pay close attention to Puma Biotechnology (PBYI) stock based on the movements in the options market lately.
Puma Biotechnology, Inc. , a biopharmaceutical company, and Medison Pharma Ltd, Israel's leading commercial partner for innovative pharmaceuticals, have entered into an exclusive agreement under which Medison will commercialize NERLYNX® in Israel.
Puma Biotechnology, Inc. , a biopharmaceutical company, today announced that on January 16, 2018 the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement stock option to purchase 90,000 shares of Puma common stock to Douglas Hunt in connection with Mr.
NEW YORK, NY / ACCESSWIRE / January 25, 2018 / It was a rough day of trading on Wednesday for biotech giants Valeant Pharmaceuticals and Puma Biotechnology. Valeant was given a "sell" rating ...
Puma's (PBYI) shares decline after CHMP conveyed the company that the former will probably vote against the approval of breast cancer drug Nerlynx at the CHMP meeting scheduled in February.
Amarin Corporation plc (NASDAQ:AMRN) and Puma Biotechnology, Inc. (NASDAQ:PBYI) both updated markets as to the progress of their respective lead development programs early this week and both fresh inputs have translated to movement in the companies’ share prices. Here’s what happened. Amarin Amarin is trying to get an asset called Vascepa to market in the […] The post Here’s What’s Moving Amarin Corporation and Puma Biotechnology appeared first on Market Exclusive.
Puma Biotechnology Inc. shares dropped 26.7% in premarket trade on Wednesday after the company said a European Medicines Agency committee completed a negative vote for its breast cancer therapy neratinib, ...
Puma Biotechnology Inc. shares fell Tuesday after the biotech company said it will likely not get a positive result on its European marketing application for a breast cancer treatment. Puma Biotechnology ...
Puma Biotechnology, Inc. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has communicated a negative trend vote after meeting with the Company today to discuss the Marketing Authorisation Application for neratinib for the extended adjuvant treatment of early stage HER2-positive breast cancer.
Puma's (PBYI) shares jump in a year's time on its cancer drug Nerlynx's approval in the United States coupled with strategic collaborations.
Aradigm Corporation (NASDAQ:ARDM) and Puma Biotechnology, Inc. (NASDAQ:PBYI) both served up key updates in the biotechnology space this week, with each relating to a respective in-house development program. Here’s what happened with each company and what comes next for both. Aradigm Aradigm announced on Thursday that the FDA Antimicrobial Drugs Advisory Committee did not recommend […] The post Biotech Updates: Aradigm Corporation & Puma Biotechnology appeared first on Market Exclusive.
Puma, Clovis and Incyte could outperform other midcap biotechs this year, an analyst says, listing the trio as his favorites for 2018.
Puma Biotechnology, Inc. , a biopharmaceutical company, has been selected for addition to the NASDAQ Biotechnology Index as part of the NBI’s annual re-ranking of biotechnology and pharmaceutical companies listed on The NASDAQ Stock Market® that meet NBI’s eligibility criteria.
NEW YORK, NY / ACCESSWIRE / December 14, 2017 / Shares of Puma Biotechnology closed up over 5% yesterday on news regarding the European Medicines Agency. Shares of Intercept Pharmaceuticals soared higher ...